Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Preventive Vaccines Market size was valued at US$ 88,430.0 million in 2023 and projected to reach at US$ 97,519.8 million by 2030 is poised to grow at 1.4% CAGR from 2024-2030. Ongoing worldwide initiatives and vaccination programs, sponsored by organizations such as the World Health Organization (WHO) and Gavi, the Vaccine Alliance, play critical roles in promoting immunization and increasing access to preventative vaccines. These programs help to raise knowledge and adoption of vaccines worldwide. Furthermore, advances in vaccine production technologies, such as recombinant DNA technology, mRNA-based vaccines, and vector-based vaccinations, have resulted in the creation of more effective and targeted preventive vaccines. Continuous innovation improves vaccine efficacy, safety, and scalability.
Study Period
2024-2030Base Year
2023CAGR
1.4%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Rising prevalence of infectious diseases are the primary factor driving demand for preventative vaccinations throughout the forecast period. According to the Global Tuberculosis Report 2021, published by WHO in October 2021, most tuberculosis cases were found in the WHO regions of Southeast Asia (43%), Africa (25%), and Western Pacific (18%), with fewer cases found in the Eastern Mediterranean (8.3%) and Europe (2.3%). Thus, the increased prevalence of tuberculosis in the population enhances the demand for prevention, which is expected to drive market growth throughout the forecast period. Furthermore, the emergence of genetic engineering, vaccine delivery technologies, and proteomics has accelerated vaccine technological advancements. This is projected to encourage the development of preventative vaccine products, which would help the market grow. However, the danger of adverse effects and the high cost of vaccine development are expected to limit market growth throughout the projection period.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is expected to grow in the preventive vaccines market over the forecast period due to factors such as rising infectious disease prevalence, increased demand for vaccines, a growing geriatric population at risk of developing infectious diseases, and the presence of key market players. Growing government and international funding to speed the development of preventative vaccinations in the country is also projected to drive market expansion. Furthermore, the developing company's focus on various business tactics, such as collaboration, partnership, agreement, launches, and facility development, among others, is projected to create chances and make preventative vaccinations more available in the marketplace. This is expected to propel market expansion throughout the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 88,430.0 million |
|
Market Size in 2030 |
US$ 97,519.8 million |
|
Market CAGR |
1.4% |
|
By Type |
|
|
By Disease Type |
|
|
By Region |
|
Download Free Sample Report
The Preventive Vaccines Market was valued at US$ 88,430.0 million in 2023 and is projected to reach US$ 97,519.8 million by 2030, growing at a CAGR of 1.4%.
The rising occurrence of infectious diseases such as influenza, hepatitis, polio, measles, and others increase the need for preventative immunizations.
Advances in vaccine development technologies, such as recombinant DNA technology, mRNA-based vaccines, and vector-based vaccines, have resulted in the creation of more effective and targeted preventive vaccines.
Market research is segmented based on type, Disease type, and region.
North America is estimated to dominate with the highest CAGR over the forecast period.
| 1.Executive Summary |
| 2.Global Preventive Vaccines Market Introduction |
| 2.1.Global Preventive Vaccines Market - Taxonomy |
| 2.2.Global Preventive Vaccines Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Disease Type |
| 2.2.3.Region |
| 3.Global Preventive Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Preventive Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Preventive Vaccines Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Inactivated Vaccines |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Live Attenuated Vaccines |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Subunit |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Conjugate Vaccines |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Preventive Vaccines Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Measles |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Polio |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Influenza |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Hepatitis |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Mumps |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Preventive Vaccines Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Inactivated Vaccines |
| 8.1.2.Live Attenuated Vaccines |
| 8.1.3.Subunit |
| 8.1.4.Conjugate Vaccines |
| 8.1.5.Others |
| 8.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Measles |
| 8.2.2.Polio |
| 8.2.3.Influenza |
| 8.2.4.Hepatitis |
| 8.2.5.Mumps |
| 8.2.6.Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Inactivated Vaccines |
| 9.1.2.Live Attenuated Vaccines |
| 9.1.3.Subunit |
| 9.1.4.Conjugate Vaccines |
| 9.1.5.Others |
| 9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Measles |
| 9.2.2.Polio |
| 9.2.3.Influenza |
| 9.2.4.Hepatitis |
| 9.2.5.Mumps |
| 9.2.6.Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Inactivated Vaccines |
| 10.1.2.Live Attenuated Vaccines |
| 10.1.3.Subunit |
| 10.1.4.Conjugate Vaccines |
| 10.1.5.Others |
| 10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Measles |
| 10.2.2.Polio |
| 10.2.3.Influenza |
| 10.2.4.Hepatitis |
| 10.2.5.Mumps |
| 10.2.6.Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Inactivated Vaccines |
| 11.1.2.Live Attenuated Vaccines |
| 11.1.3.Subunit |
| 11.1.4.Conjugate Vaccines |
| 11.1.5.Others |
| 11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Measles |
| 11.2.2.Polio |
| 11.2.3.Influenza |
| 11.2.4.Hepatitis |
| 11.2.5.Mumps |
| 11.2.6.Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Preventive Vaccines Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Inactivated Vaccines |
| 12.1.2.Live Attenuated Vaccines |
| 12.1.3.Subunit |
| 12.1.4.Conjugate Vaccines |
| 12.1.5.Others |
| 12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Measles |
| 12.2.2.Polio |
| 12.2.3.Influenza |
| 12.2.4.Hepatitis |
| 12.2.5.Mumps |
| 12.2.6.Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Sanofi |
| 13.2.2.Johnson& Jonson |
| 13.2.3.Moderna Inc |
| 13.2.4.Sinovac Biotech Ltd |
| 13.2.5.Pfizer Inc |
| 13.2.6.GlaxoSmithKline plc |
| 13.2.7.Merck & Co. Inc |
| 13.2.8.CSL Limited |
| 13.2.9.Novartis AG |
| 13.2.10.Bharat Biotech |
| 13.2.11.Serum Institute |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.